Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries

被引:20
|
作者
Garattini, Livio [1 ]
Motterlini, Nicola [1 ]
Comago, Dante [1 ]
机构
[1] Mario Negri Inst Pharmacol Res, Ctr Hlth Econ, CESAV, I-24020 Ranica, Italy
关键词
distribution margins; Europe; pharmaceuticals; prices;
D O I
10.1016/j.healthpol.2007.08.005
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To compare prices of in-patent active ingredients (AIs) in Europe at three levels (ex-factory prices, net distribution margins and third party payers' prices). Methods: We compared the prices in seven EU countries (Belgium, France, Germany, Italy, the Netherlands, Spain and the UK) of the 20 in-patent AIs most sold on the Italian retail market in 2004, based on "sell in" sales data. We calculated the average ex-factory price per unit of each compound in each of the seven countries, weighted by the volumes of all reimbursable package sizes and strengths. We estimated net distribution margins according to the 2004 domestic regulations by deducting any type of mandatory discount. Finally, we added VAT to calculate "third party payer's prices". All prices were expressed in index numbers (Italy= 100). Results: Italy had the lowest average ex-factory prices, the Netherlands and particularly the UK had by far the lowest distribution margins, while Germany had by far the highest third party payers' prices. The Netherlands and particularly UK showed a steep decrease from ex-factory to third party payers' prices, while Belgium, Italy and Spain gave the opposite pattern. Conclusions: Our study suggests that public authorities can deal with drug prices both by strictly controlling ex-factory prices and by establishing appropriate distribution margins. The latter might be facilitated by liberalizing the distribution sector. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:305 / 313
页数:9
相关论文
共 50 条
  • [1] Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis
    Garattini, Livio
    Cornago, Dante
    De Compadri, Paola
    [J]. HEALTH POLICY, 2007, 82 (03) : 330 - 339
  • [2] A comparison of generic drug prices in seven European countries: a methodological analysis
    Olivier J. Wouters
    Panos G. Kanavos
    [J]. BMC Health Services Research, 17
  • [3] A comparison of generic drug prices in seven European countries: a methodological analysis
    Wouters, Olivier J.
    Kanavos, Panos G.
    [J]. BMC HEALTH SERVICES RESEARCH, 2017, 17
  • [4] COMPARISON OF ORPHAN DRUGS PRICES: A EUROPEAN COMPARISON
    Hanna, E.
    Chachoua, L.
    Achour, L.
    Dabbous, M.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S86 - S86
  • [5] COMPARISON OF SELECTED DRUGS PRICES IN EU COUNTRIES
    Psenkova, Bucek M.
    Mackovicova, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S164 - S164
  • [6] The causality between house prices and stock prices: evidence from seven European countries
    Irandoust, Manuchehr
    [J]. INTERNATIONAL JOURNAL OF HOUSING MARKETS AND ANALYSIS, 2021, 14 (01) : 137 - 156
  • [7] INNOVATIVITY: A COMPARISON ACROSS SEVEN EUROPEAN COUNTRIES
    Mohnen, Pierre
    Mairesse, Jacques
    Dagenais, Marcel
    [J]. ECONOMICS OF INNOVATION AND NEW TECHNOLOGY, 2006, 15 (4-5) : 391 - 413
  • [8] COMPARISON RETAIL PRICES OF DRUG PRICES BETWEEN TURKEY AND EUROPEAN COUNTRIES
    Kockaya, G.
    Atikeler, K.
    Esen, A.
    Tuna, E.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A457 - A457
  • [9] Comparison of Cardiovascular Medicines Prices in Four European Countries
    Mitkova, Zornitsa
    Vasileva, Mariya
    Savova, Alexandra
    Manova, Manoela
    Terezova, Silvia
    Petrova, Guenka
    [J]. FRONTIERS IN PUBLIC HEALTH, 2020, 8
  • [10] Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices
    Aniek Dane
    Anne-Sophie Klein Gebbink
    Jan-Dietert Brugma
    Albane Degrassat-Théas
    Martin J. Hug
    Morten B. Houlind
    P. Paubel
    P. Hugo M. van der Kuy
    Carin A. Uyl-de Groot
    [J]. Applied Health Economics and Health Policy, 2023, 21 : 905 - 914